Recent posts
View all
health-issue
Media Update: New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
https://ift.tt/aoqECAH New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediat…
Read more
health-issue
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
https://ift.tt/xm79v8C Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance from Sanofi - Aventis Groupe https://ift…
Read more
health-issue
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
https://ift.tt/RTNLqsW Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia from Sanofi - Aventis Groupe https://ift…
Read more
health-issue
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
https://ift.tt/EC0Dfb2 New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis from Sanofi - Avent…
Read more
health-issue
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
https://ift.tt/A0ToFrW from Sanofi - Aventis Groupe https://ift.tt/QMy8utp via IFTTT
Read more
health-issue
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
https://ift.tt/MkUtvnu New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis from …
Read more
health-issue
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
https://ift.tt/7IHisUh from Sanofi - Aventis Groupe https://ift.tt/z2ouJMf via IFTTT
Read more